We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
21.7
quarters
Top 10 Avg Time Held
6.6
quarters
Top 20 Avg Time Held
9.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1451
CVS Health
CVS
$114B
| $266K | ﹤0.01% |
3,858
-540
| -12% | -$35.4K |
2013 Q2
48 quarters
|
|
1452
CG Oncology
CGON
$5.5B
| $265K | ﹤0.01% |
10,200
+1,700
| +20% | +$41K |
2024 Q4
2 quarters
|
|
1453
Kratos Defense & Security Solutions
KTOS
$7.49B
| $263K | ﹤0.01% |
+5,661
| New | +$205K |
2025 Q2
0 quarters
|
|
1454
Sunstone Hotel Investors
SHO
$2.15B
| $260K | ﹤0.01% |
30,000
+16,800
| +127% | +$145K |
2025 Q1
1 quarter
|
|
1455
Amphastar Pharmaceuticals
AMPH
$1.12B
| $258K | ﹤0.01% |
11,224
-573,891
| -98% | -$14.2M |
2014 Q3
43 quarters
|
|
1456
DELISTED
PotlatchDeltic
PCH
| $256K | ﹤0.01% |
6,677
-112
| -2% | -$4.4K |
2013 Q2
48 quarters
|
|
1457
Oneok
OKE
$58.3B
| $255K | ﹤0.01% |
3,120
+383
| +14% | +$31.9K |
2020 Q4
18 quarters
|
|
1458
DELISTED
Hess
HES
| $254K | ﹤0.01% |
1,831
-58
| -3% | -$7.83K |
2013 Q2
48 quarters
|
|
1459
DELISTED
Integral Ad Science
IAS
| $249K | ﹤0.01% |
30,000
+3,000
| +11% | +$22.9K |
2024 Q2
4 quarters
|
|
1460
Arthur J. Gallagher & Co
AJG
$60.2B
| $248K | ﹤0.01% |
775
-343
| -31% | -$113K |
2013 Q2
48 quarters
|
|
1461
Relay Therapeutics
RLAY
$3.73B
| $246K | ﹤0.01% |
71,217
-25,096
| -26% | -$74.6K |
2024 Q1
5 quarters
|
|
1462
Ralph Lauren
RL
$22.2B
| $244K | ﹤0.01% |
889
+226
| +34% | +$55.9K |
2023 Q2
8 quarters
|
|
1463
PG&E
PCG
$38.8B
| $242K | ﹤0.01% |
17,389
+7,749
| +80% | +$126K |
2022 Q3
11 quarters
|
|
1464
NXP Semiconductors
NXPI
$55.6B
| $240K | ﹤0.01% |
1,099
-18
| -2% | -$3.52K |
2013 Q2
48 quarters
|
|
|
WSR
1465
DELISTED
Whitestone REIT
WSR
| $233K | ﹤0.01% |
18,662
+1,014
| +6% | +$12.9K |
2022 Q1
13 quarters
|
|
1466
Neumora Therapeutics
NMRA
$66.5M
| $230K | ﹤0.01% |
314,119
+29,543
| +10% | +$22.4K |
2025 Q1
1 quarter
|
|
1467
Haemonetics
HAE
$5.49B
| $228K | ﹤0.01% |
3,062
+72
| +2% | +$4.77K |
2015 Q4
38 quarters
|
|
1468
Concentrix
CNXC
$1.63B
| $227K | ﹤0.01% |
4,294
+1,930
| +82% | +$102K |
2020 Q4
18 quarters
|
|
1469
Aon
AON
$58.2B
| $227K | ﹤0.01% |
635
-324
| -34% | -$117K |
2013 Q2
48 quarters
|
|
1470
Synopsys
SNPS
$92.5B
| $226K | ﹤0.01% |
440
-5
| -1% | -$2.33K |
2013 Q2
48 quarters
|
|
1471
Hilton Grand Vacations
HGV
$2.7B
| $224K | ﹤0.01% |
5,391
-484
| -8% | -$18.3K |
2023 Q1
9 quarters
|
|
1472
Mineralys Therapeutics
MLYS
$1.88B
| $224K | ﹤0.01% |
16,528
+4,577
| +38% | +$66.3K |
2023 Q2
8 quarters
|
|
1473
EchoStar
ECHO
$25.9B
| $223K | ﹤0.01% |
8,068
+1,576
| +24% | +$34.6K |
2025 Q1
1 quarter
|
|
1474
DELISTED
Hanesbrands
HBI
| $223K | ﹤0.01% |
48,625
+31,202
| +179% | +$151K |
2023 Q4
6 quarters
|
|
1475
Old Second Bancorp
OSBC
$1.26B
| $222K | ﹤0.01% |
12,515
+113
| +0.9% | +$1.84K |
2015 Q1
41 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.